Sustainability - Sustainability plan - Recordati

Sustainability Plan

The Sustainability Plan is the tool used to share the Group’s future trajectory with its stakeholders: it represents an expression of the ambitions of the Recordati Group and the commitments it wishes to prioritise in order to promote sustainable and responsible growth.

The Sustainability Plan focuses on five priority areas: Patient care, People care, Environmental protection, Responsible sourcing, Ethics and integrity.

Patient Care

Driven by its purpose, Recordati is focused on improving people’s health and quality of life. At Recordati, we’ve always believed that health, and the opportunity to live life to the fullest, is a right, not a privilege.

Whether for common diseases or the rarest, we want to give everyone the opportunity to be the best version of themselves by having access to affordable and innovative healthcare.

People Care

We are committed to creating a safe and inclusive working environment where everyone can express their talents. Our Employees are our most important asset and, therefore, we recognise and value the role that each person plays in the success of our business.

We aim to create shared value and positively contribute to sustainable development where we operate, aware of the importance of dialogue, collaboration and respect for the community.

Environmental Protection

Improving human health is the cornerstone of Recordati’s purpose, but we are aware that the health and well-being of present and future generations and the health of our planet are closely interlinked.

With this in mind, we want to take conscious action by working to preserve natural resources and contribute to the fight against climate change by minimising our environmental impact.

Responsible Sourcing

We want to build relationships based on transparency and trust with suppliers and strategic partners. We are committed to constantly promoting respect for ethical, environmental and social aspects along the entire value chain.

Ethics and Integrity

Integrity is non-negotiable for us. We demonstrate our leadership by setting a good example and our daily actions are driven by the principles of fairness and transparency.

Below are the objectives of the Group’s Sustainability Plan. For more details, please refer to the Consolidated Sustainability Statement.

Business ethics, integrity and anti-corruption

• Publication of the new Group Code of Ethics and related training delivered to at least 90% of Group employees by 2026.
• Update the Anti-Bribery Manual and roll-out in 2026, with a target of at least 90% of Group employees to receive training by 2027.

Privacy Continue to deliver training to Group employees on data protection by 2026:

• Extend training on the Global Privacy Policy to all new employees.
• Launch three micro-learning initiatives to allow employees to expand on their understanding and knowledge of relevant topics.

Access to medicine and healthcare, research and development In the field of rare diseases, the Group is committed to:

• Continuing with Patient Assistance Program (PAP), Co-Pay Assistance Program (CAP) or similar programs aimed at providing assistance to patients who are eligible to receive financial support for products (2026).
• Continuing to work closely with rare-disease communities (including doctors, healthcare professionals, patient groups and families) to increase awareness, facilitate improved diagnosis and expand availability of treatments for people with rare diseases (2026).
• Continuing to expand rare disease and orphan drugs innovation pipeline and R&D of new therapies (2026). Main activities:
  • Endocrinology:
    • Clinical trial initiation (starting enrolment) to test Isturisa efficacy in treating less severe Cushing patients with hypertension with a lower starting dose.
    • Post-Bariatric Hypoglycaemia (PBH) Phase 2 top line results by the second trimester and go/no go decision after meeting with the Regulatory authority
  • Hema-Oncology:
    • Dinutuximab beta for the treatment of high-risk relapsed/ refractory neuroblastoma in the US: to enrol patients needed to submit BLA.
    • Dinutuximab beta for the treatment of Ewing sarcoma: to continue Phase 1 study and taking a decision on the program after regulatory feedback and Phase 1 results.
    • Enjamo in Immune thrombocytopenic purpura (ITP): go/no go decision expected Q1 2026, following FDA Phase 3 feedback.

Partnering with the patient community: actively involving patients at every stage of a medicine’s journey to ensure treatments reflect real patient needs, experiences, and outcomes.

In the context of the Specialty & Primary Care Division, the Group is committed to:

• Continuing to organise health caravans in Tunisia’s underserved regions to improve access to essential medical care and screening (2026).

Product quality and safety Continuing to guarantee the highest product quality and safety standards throughout the product life cycle to ensure patient safety, which is the fundamental priority in all of Recordati’s operations. In terms of specific projects, Recordati is working on the further digitalisation of the quality processes, with the following aims:

• Complete the introduction of a digital system to manage quality-related events (Veeva QMS) in 2025-2026.
• Expand the document management digital system of the Recordati commercial subsidiaries in 2026.
• Adopt an electronic LIMS (Laboratory Information Management System) for quality control at the Group’s manufacturing sites that makes it possible to digitally control and approve the results of analytical testing.

Diversity and equal opportunities 1

• Increase the percentage of women in Top and Senior Manager positions to 38% by 2028 (base year: 31% in 2023).
• Completion of the first three D&I training modules (Introduction to D&I at Recordati, Our 5-step approach, and Unconscious bias) by at least 80% of Top and Senior Managers by 2026 (base year 2025, 69%).
• Maintain an inclusion index score of at least 80% in the next People Engagement Survey, to take place in 2027.

Engagement

• Continue to conduct the People Engagement Survey every two years, involving all Group employees and maintaining a participation rate of at least 80% (next survey in 2027).
• Hold a pulse survey to gather insight and feedback from employees on the progress made with reference to the action plans of the full survey (the next pulse survey is planned in 2026).

Talent attraction and development

• Continue to support the global learning culture by promoting training initiatives: through access to an international e-learning platform, which contains a library of approximately 25,000 optional/non-mandatory courses; through the internal portal, which contains all the mandatory courses (such as those on health and safety, pharmacovigilance, ethics, etc.) (2026).
• Reach at least 85% of employees in 2026 who identified professional growth targets through an individual development plan (IDP) (base year 2024: 45.8%; 80% in 2025).

Health and Safety

• Obtaining ISO 45001 certification for Group Plants covering about 80% of plant employees by 2030 (calculated based on plant employee data for 2023).
• In 2026, obtaining ISO 45001 certification at the Turkish plant (covering approximately 35% of employees who work at the Group’s plants).
• Continue the EHS Engagement & Leadership Program to further reinforce the health and safety culture at all Group plants (2027).

Support for local communities

• Continue to support for communities in areas where the Group operates through donations (monetary and/or product donations) and other initiatives (including employee volunteer activities) (2026).

1. All initiatives aimed at achieving these targets are implemented in full compliance with applicable laws and regulations.

Fight against climate change

• Increase of renewable energy installed power capacity to 11,000 kWp by 2026 (386 kWp in 2022). (target: 800 kWp in 2024; 5,600 kWp in 2025; 11,000 kWp in 2026).
• Continue to purchase 100% renewable electricity for plants located in countries where this is possible.1
• Reduce Scope 1 and Scope 2 market-based CO2eq emissions by 20% by 2030, using 2022 as a baseline.2
• Obtaining ISO 50001 certification for various Group plants accounting for at least 90% of energy consumption by 2029 (base year for energy consumption data: 2023).

All environmental aspects (water, waste, pollution)

• Obtaining ISO 14001 certification for various Group plants accounting for at least 90% of the waste produced by 2027 (base year for waste production data: 2023).
• In 2026, achievement of ISO 14001 certification at the plants in Spain and Türkiye, covering approximately 80% of waste produced by all Group plants.

Responsible waste management and circular economy initiatives

• Continue with the analysis of possible packaging solutions with lower environmental impact (2025-2027).
• Continue with the analysis of possible new initiatives for the recovery and reuse of chemical raw materials used in production processes (2025-2027).

The Sustainability Plan, defined in accordance with the materiality analysis, also highlights the contribution to the achievement of 10 of the 17 Sustainable Development Goals (SDGs) of the 2030 Agenda, the common goals signed by UN member states that outline a path of collaboration and responsibility to confront today’s complex challenges.